Insulin analogues use in pregnancy among women with pregestational diabetes mellitus and risk of congenital anomaly: a retrospective population-based cohort study
Open Access
Abstract
Objectives To evaluate the risk of major congenital anomaly associated with first-trimester exposure to insulin analogues compared with human insulin in offspring of women with pregestational diabetes. Design and setting A population-based cohort of women with pregestational diabetes (n=1661) who delivered between 1996 and 2012 was established retrospectively from seven European regions covered bythe European Surveillance of Congenital Anomalies (EUROCAT) congenital anomaly registries. Primary outcome measures The risk of non-chromosomal major congenital anomaly in live births, fetal deaths and terminations for a fetal anomaly exposed to insulin analogues in the first trimester of pregnancy was compared with the risk in those exposed to human insulin only. Results During the first trimester, 870 fetuses (52.4%) were exposed to human insulin only, 397 fetuses (23.9%) to insulin analogues only and 394 fetuses (23.7%) to both human insulin and insulin analogues. The risk of major congenital anomaly in fetuses exposed to insulin analogues only was lower than those exposed to human insulin only; the relative risk adjusted for glycaemic control and region was 0.56 (95% CI 0.29 to 1.06). The significantly lower risk related to exposure of insulin analogues only was observed in congenital heart defects: adjusted relative risk 0.14 (95% CI 0.03 to 0.62). Conclusions In this retrospective population-based cohort study across Europe, first-trimester exposure to insulin analogues did not increase the risk of major congenital anomaly compared with exposure to human insulin. A possible lower risk of congenital heart defects among fetuses exposed to insulin analogues only deserves further investigation.Keywords
Funding Information
- The European Commission
This publication has 29 references indexed in Scilit:
- Spectrum of congenital anomalies in pregnancies with pregestational diabetesBirth Defects Research Part A: Clinical and Molecular Teratology, 2012
- Paper 1: The EUROCAT network—organization and processes†Birth Defects Research Part A: Clinical and Molecular Teratology, 2011
- Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysisBMC Pregnancy and Childbirth, 2010
- New Dutch reference curves for birthweight by gestational ageEarly Human Development, 2009
- Obstetric and Perinatal Outcomes in Type 1 Diabetic PregnanciesDiabetes Care, 2009
- Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based studyBMJ, 2006
- Threshold values of maternal blood glucose in early diabetic pregnancy - prediction of fetal malformationsActa Obstetricia et Gynecologica Scandinavica, 2005
- Threshold values of maternal blood glucose in early diabetic pregnancy – prediction of fetal malformationsActa Obstetricia et Gynecologica Scandinavica, 2004
- Why Do Diabetic Women Deliver Malformed Infants?Clinical Obstetrics and Gynecology, 2000
- Elevated Maternal Hemoglobin A1Cin Early Pregnancy and Major Congenital Anomalies in Infants of Diabetic MothersNew England Journal of Medicine, 1981